Literature DB >> 34740476

TLR genetic variation is associated with Rotavirus-specific IgA seroconversion in South African Black infants after two doses of Rotarix vaccine.

Thabiso V Miya1, Michelle J Groome2, Debra de Assis Rosa3.   

Abstract

Live oral rotavirus vaccines have significantly reduced rotavirus-related diarrheal morbidity and mortality globally, but low efficacy of these vaccines is observed in low-income countries where disease burden is highest. The biological basis of rotavirus vaccine failure remains unknown but likely includes both microbial and host factors. We investigated associations between 19 candidate SNPs in the TLR3, TLR7, TLR8, DDX58 and IFIH1 genes that play a role in innate immunity, and seroconversion in Black South African infants after vaccination with Rotarix at 6 and 14 weeks of age. Rotavirus-specific IgA antibody titre was measured by ELISA before each vaccine dose and four weeks after the second dose, and seroconversion was defined as a four-fold or greater increase in IgA antibody titre at 18 weeks of age when compared to pre-vaccine titres. A total of 95/138 individuals seroconverted (68.8%) and seroconversion was significantly affected by birthweight (P = 0.010), pre-vaccine IgA and IgG titres (P = 0.0002 and P = 0.007 respectively). rs2159377 SNP in TLR8 was significantly associated with seroconversion in a univariate allelic model (P = 0.015) and was borderline significant in a multivariable logistic regression adjusted for birthweight and pre-vaccine titres (P = 0.071), although these values did not remain significant after Bonferroni correction. A haplotype of six SNPs on the X chromosome across TLR7 and TLR8, including rs179008 and rs5935438 minor alleles, was significantly associated with seroconversion in a univariate model (P = 0.042), but not in a multivariable model or after Bonferroni correction. Epistatic interaction between rs5743305 in TLR3 and rs55789327 in DDX58 was significantly associated with seroconversion (P = 0.034) but a genetic risk score constructed from all 19 minor alleles was not. Our results suggest that TLR variants may influence IgA antibody production and seroconversion to Rotarix vaccine in South Africans. Host genetic variation contributes to the varying immunogenicity of live oral rotavirus vaccines.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Innate immunity; RIG-like receptors; Rotavirus; Toll like receptors, host genetics, seroconversion; Vaccine

Mesh:

Substances:

Year:  2021        PMID: 34740476      PMCID: PMC8678908          DOI: 10.1016/j.vaccine.2021.10.051

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants.

Authors:  Carl T D'Angio; Roy J Heyne; Shahnaz Duara; Lucy C Holmes; T Michael O'Shea; Hongyue Wang; Dongwen Wang; Pablo J Sánchez; Robert C Welliver; Rita M Ryan; Kenneth C Schnabel; Caroline B Hall
Journal:  Pediatr Infect Dis J       Date:  2011-07       Impact factor: 2.129

2.  Prevaccination Rotavirus Serum IgG and IgA Are Associated With Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in South African Infants.

Authors:  Sung-Sil Moon; Michelle J Groome; Daniel E Velasquez; Umesh D Parashar; Stephanie Jones; Antoinette Koen; Nadia van Niekerk; Baoming Jiang; Shabir A Madhi
Journal:  Clin Infect Dis       Date:  2015-09-23       Impact factor: 9.079

3.  SNP genotyping using the Sequenom MassARRAY iPLEX platform.

Authors:  Stacey Gabriel; Liuda Ziaugra; Diana Tabbaa
Journal:  Curr Protoc Hum Genet       Date:  2009-01

Review 4.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

5.  Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.

Authors:  Nigel A Cunliffe; Desiree Witte; Bagrey M Ngwira; Stacy Todd; Nancy J Bostock; Ann M Turner; Philips Chimpeni; John C Victor; A Duncan Steele; Alain Bouckenooghe; Kathleen M Neuzil
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

6.  Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.

Authors:  S A Madhi; M Kirsten; C Louw; P Bos; S Aspinall; A Bouckenooghe; K M Neuzil; A D Steele
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

7.  Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa.

Authors:  Michelle J Groome; Sung-Sil Moon; Daniel Velasquez; Stephanie Jones; Anthonet Koen; Nadia van Niekerk; Baoming Jiang; Umesh D Parashar; Shabir A Madhi
Journal:  Bull World Health Organ       Date:  2014-02-04       Impact factor: 9.408

8.  Mutations in toll-like receptor 3 are associated with elevated levels of rotavirus-specific IgG antibodies in IgA-deficient but not IgA-sufficient individuals.

Authors:  Gökçe Günaydın; Johan Nordgren; Lennart Svensson; Lennart Hammarström
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

9.  Genetic variation in TLR genes in Ugandan and South African populations and comparison with HapMap data.

Authors:  Allison R Baker; Feiyou Qiu; April Kaur Randhawa; David J Horne; Mark D Adams; Muki Shey; Jill Barnholtz-Sloan; Harriet Mayanja-Kizza; Gilla Kaplan; Willem A Hanekom; W Henry Boom; Thomas R Hawn; Catherine M Stein
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants.

Authors:  James A Church; Bernard Chasekwa; Sandra Rukobo; Margaret Govha; Benjamin Lee; Marya P Carmolli; Robert Ntozini; Kuda Mutasa; Monica M McNeal; Florence D Majo; Naume V Tavengwa; Beth D Kirkpatrick; Lawrence H Moulton; Jean H Humphrey; Andrew J Prendergast
Journal:  Vaccine       Date:  2020-02-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.